Evidence map›Paper›PMID 21528051›Full record

ReviewWorld journal of gastroenterology2011

Role of conventional therapies in the era of biological treatment in Crohn's disease.

Paolo Gionchetti, Carlo Calabrese, Rosy Tambasco, Ramona Brugnera, Giulia Straforini, Giuseppina Liguori, Giulia Spuri Fornarini, Donatella Riso, Massimo Campieri, Fernando Rizzello

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Paolo GionchettiDepartment of Clinical Medicine, University of Bologna, 40138 Bologna, Italy. paolo.gionchetti@unibo.it
Carlo Calabrese
Rosy Tambasco
Ramona Brugnera
Giulia Straforini
Giuseppina Liguori
Giulia Spuri Fornarini
Donatella Riso
Massimo Campieri
Fernando Rizzello
University of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized, placebo-controlled trials, and meta-analyses when available, that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD, modifying the treatment goals. However, the large majority of patients with CD will be managed through conventional therapy, even if they are a prelude to biological therapy.

Indexed as

Crohn DiseaseHumansMeta-Analysis as TopicPlacebosRandomized Controlled Trials as TopicRemission InductionPlacebos5-Aminosalicylic acid6-MercaptopurineAnti-tumor necrosis facto-αAzathioprineBiological therapiesCrohn’s diseaseSulfasalazine

Identifiers

PMID21528051
PMCPMC3080713
OpenAlexW2053996565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.